Reflections: What Really Matters  |  Teacher Insights: New Harvard Online course course prepares professionals for a data-driven world  |  Parent Interventions: Research shows lullabies in any language relax babies  |  International Edu News: 'Plastic bags could be 'eco-friendlier' than paper and cotton bags'  |  Leadership Instincts: Start-up with plastic waste recycling solution wins top prize at ideasinc 2020  |  International Edu News: Frailty, old age and comorbidity main predictors of death from Covid-19  |  Leadership Instincts: Cyber centre to reduce digital harm  |  Policy Indications: New funding to improve water security for 10 million people in Africa and Asia  |  International Edu News: UCL hosts global conference on UN Sustainable Development Goals  |  International Edu News: Medium-term impact of COVID-19 revealed in new study  |  International Edu News: Extremely rapid diagnostic test for Covid-19  |  Teacher Insights: Cambridge University Press to join with Cambridge Assessment  |  National Edu News: Minister inaugurates new Diamond Jubilee Lecture Hall Complex of NIT Jamshedpur  |  Education Information: CSIR partnered clinical trials website “CUReD” on Repurposed Drugs for Covid- 19  |  Teacher Insights: The 6th India International Science Festival to be held in Virtual format  |  
August 22, 2020 Saturday 01:27:53 PM IST

Oral nanomedicine may bring relief for Kala-Azar & other neglected diseases

Science Innovations

Patients affected by Kala- Azar, scientifically called Visceral leishmaniasis (VL), one of the most neglected tropical diseases may soon find relief in an oral nanomedicine from India. The oral therapeutics could help in the control and elimination of VL, around 95 % of which is reported from Bangladesh, Brazil, China, Ethiopia, India, Kenya, Nepal, Somalia, South Sudan, and Sudan. Scientists from the Institute of Nano Science & Technology (INST), Mohali, an autonomous institute of the Department of Science & Technology, Govt. of India, have developed an oral nanomedicine with the help of surface-modified solid lipid nanoparticles based combinational cargo system for combating visceral leishmaniasis. The findings of their study supported by the DST-SERB Early Career Research Award have been recently published in the journals ‘Scientific Reports’ and ‘Materials Science & Engineering C’.

According to the INST team, till-date there is no study reported where a combination of two anti-leishmanial drugs has been delivered through nanomodification as a potential therapeutic strategy against visceral leishmaniasis. This work suggests the superiority of as-prepared modified formulation (m-DDSLNs) surface modified with 2-hydroxypropyl-β-cyclodextrin (HPCD) as a promising approach towards the oral delivery of anti-leishmanial drugs.

In this study by INST team led by Dr. Shyam Lal M anti-leishmanial drugs Amphotericin B (AmB) & Paromomycin (PM) were encapsulated in solid lipid nanoparticles and further modified with 2-hydroxypropyl-β-cyclodextrin (HPCD). The scientists explored the oral therapeutic potential of the formulation in the treatment of visceral leishmaniasis. They employed an emulsion solvent evaporation method to prepare HPCD modified dual drug-loaded solid lipid nanoparticles (m-DDSLNs). The nanoparticle-based combinatorial drug delivery system developed by them enhanced the efficacy of the formulation in both in vitro and in vivo models by reducing intracellular amastigote growth in L. donovani-infected macrophages and hepatic parasite burden in L. donovani-infected BALB/c mice model, respectively without causing any significant toxic side effects.

According to the INST team, the solid lipid nanoparticles (SLNs) can help enhance the oral uptake of the therapeutic agent by retaining a solubilized state of the drug in the Gastrointestinal Tract and favors the formation of mixed micelles (a special case of solubilization) by inducing the secretion of bile salts and phospholipids. Further, 2-hydroxypropyl-β-cyclodextrin (HPCD) are cyclic oligosaccharides that are known to be molecular hosts which can selectively include water-insoluble guest molecules within their hydrophobic cavity through non-covalent interactions.


This study by INST team may lead to product and process patent enhancing the role of our country for developing innovative therapy against neglected diseases. The usage of lower therapeutic dose of the purified drugs through nanomodifications will be a boon in reducing toxicity, which has been a major hindrance in the existing conventional treatment when administered orally.

Comments